Core 3: Communications, Administrations, Advocacy, and Project Management
Core 3: Communications, Administrations, Advocacy, and Project Management
批准号:
10628613
负责人:
LAURA J ESSERMAN
金额:
$26.66万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
未结题
起止时间:
2017-09-08 至 2028-06-30
关键词:
AchievementAdvocacyAdvocateBreast Cancer TreatmentBudgetsClinicalClinical Drug DevelopmentCollaborationsCommunicationElementsEnsureFriendsGenerationsGoalsHuman ResourcesIndividualInfrastructureLeadershipMagnetic Resonance ImagingMeasurableMeasuresMethodologyModificationOffice of Administrative ManagementOutcomeParticipantPatient-Focused OutcomesPatientsProgram Research Project GrantsProtocols documentationRegimenRegulatory PathwayReportingResearch PersonnelRoleScienceSequential TreatmentSpecific qualifier valueStructureSubgroupTrainingTranslatingTranslational ResearchWorkdesignimaging biomarkerimprovedmalignant breast neoplasmmeetingsmolecular markernext generationnoveloperationpersonalized medicineprogramsresponse biomarkerrestrainttimelinetooltreatment responsetreatment strategytrial designwebinarworking group
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The Program Project encompasses four integrated projects to develop and maintain the infrastructure for developing and
implementing improvements in the I-SPY2.2 trial that employs early escalation/de-escalation of treatment and identifies
treatment strategies to optimize patient outcomes within a regulatory evidence generation framework. The primary aims
of the Communications, Administration, Advocacy, and Project management (CAAP) Core are to ensure program
integration, collaboration, patient acceptance, and regulatory compliance by providing project management, leadership,
and administrative support to all Projects and Cores; as well as the integration of advocacy in all patient-facing aspects of
the Projects and Core in the Program Project.
Perhaps the most critical role of the CAAP core is to coordinate the activities and deliverables of the projects and cores
with the study sponsor QLHC, its clinical operations team and the I-SPY2 trial working group chairs. While program
project personnel, cores and projects are tasked with developing and refining the technical and methodological advances
required in the continuous improvement approach employed in I-SPY2.2, all operational aspects of the trial are the
responsibility of the study sponsor. The Program Project overall PIs and project PIs, facilitated by the CAAP core, work
to integrate the changes into the operations of the trial with sponsor representatives by defining the technical
requirements, specifications, and deliverables for the sponsor’s clinical operations team.
Among its other responsibilities, the CAAP Core ensures that our patient advocates are represented on all project teams,
cores teams and inter-project collaborations, so that they can bring their unique and important perspective to help meet the
patient-centric mandate of I-SPY2.2.
Specific Aim 1: Organize, integrate, and provide administrative management of all Projects and Core
Specific Aim 2: Provide project management oversight to track milestones and timelines of the individual Projects and
Cores.
Specific Aim 3: Facilitate collaborations and disseminate information
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Enhancing the Diversity of Participants in the WISDOM Clinical Trial: Practical Challenges and Ethical Implications
-
批准号:10367828
-
项目类别:
-
资助金额:$16.15万
-
财政年份:2020
-
负责人:LAURA J ESSERMAN
-
依托单位:
Surgical Oncology Training Grant
-
批准号:10434765
-
项目类别:
-
资助金额:$30.37万
-
财政年份:2020
-
负责人:LAURA J ESSERMAN
-
依托单位:
Surgical Oncology Training Grant
-
批准号:10683105
-
项目类别:
-
资助金额:$31.4万
-
财政年份:2020
-
负责人:LAURA J ESSERMAN
-
依托单位:
Extending the Diversity, Reach, and Generalizability of the WISDOM Study
-
批准号:10368970
-
项目类别:
-
资助金额:$186.14万
-
财政年份:2020
-
负责人:LAURA J ESSERMAN
-
依托单位:
Extending the Diversity, Reach, and Generalizability of the WISDOM Study
-
批准号:10593908
-
项目类别:
-
资助金额:$181.76万
-
财政年份:2020
-
负责人:LAURA J ESSERMAN
-
依托单位:
Surgical Oncology Training Grant
-
批准号:10216206
-
项目类别:
-
资助金额:$33.14万
-
财政年份:2020
-
负责人:LAURA J ESSERMAN
-
依托单位:
Extending the Diversity, Reach, and Generalizability of the WISDOM Study
-
批准号:9888251
-
项目类别:
-
资助金额:$150.84万
-
财政年份:2020
-
负责人:LAURA J ESSERMAN
-
依托单位:
Surgical Oncology Training Grant
-
批准号:10025197
-
项目类别:
-
资助金额:$16.09万
-
财政年份:2020
-
负责人:LAURA J ESSERMAN
-
依托单位:
I-SPY2 +: Evolving the I-SPY 2 TRIAL to include MRI-directed, adaptive sequential treatment to optimize breast cancer outcomes
-
批准号:9789198
-
项目类别:
-
资助金额:$195.45万
-
财政年份:2017
-
负责人:LAURA J ESSERMAN
-
依托单位:
I-SPY2 +: Evolving the I-SPY 2 TRIAL to include MRI-directed, adaptive sequential treatment to optimize breast cancer outcomes
-
批准号:10013133
-
项目类别:
-
资助金额:$184.54万
-
财政年份:2017
-
负责人:LAURA J ESSERMAN
-
依托单位:
The I SPY 2.2 TRIAL: Evolving to Imaging and Molecular Biomarker Response Directed Adaptive Sequential Treatment to Optimize Breast Cancer Outcomes
-
批准号:10628608
-
项目类别:
-
资助金额:$268.95万
-
财政年份:2017
-
负责人:LAURA J ESSERMAN
-
依托单位:
I-SPY2 +: Evolving the I-SPY 2 TRIAL to include MRI-directed, adaptive sequential treatment to optimize breast cancer outcomes
-
批准号:9360068
-
项目类别:
-
资助金额:$233.95万
-
财政年份:2017
-
负责人:LAURA J ESSERMAN
-
依托单位:
I-SPY2 +: Evolving the I-SPY 2 TRIAL to include MRI-directed, adaptive sequential treatment to optimize breast cancer outcomes
-
批准号:10249153
-
项目类别:
-
资助金额:$180.08万
-
财政年份:2017
-
负责人:LAURA J ESSERMAN
-
依托单位:
Elucidating the molecular and contextual basis for IDLE ultralow risk lesions and the tumor immune microenvironment of high risk in situ and invasive breast cancers
-
批准号:9337415
-
项目类别:
-
资助金额:$78.25万
-
财政年份:2015
-
负责人:LAURA J ESSERMAN
-
依托单位:
Integrated Biomarkers to Characterize Breast Cancer Risk
-
批准号:7121540
-
项目类别:
-
资助金额:$81.22万
-
财政年份:2004
-
负责人:LAURA J ESSERMAN
-
依托单位:
Integrated Biomarkers to Characterize Breast Cancer Risk
-
批准号:6847727
-
项目类别:
-
资助金额:$70.0万
-
财政年份:2004
-
负责人:LAURA J ESSERMAN
-
依托单位:
Integrated Biomarkers to Characterize Breast Cancer Risk
-
批准号:7908599
-
项目类别:
-
资助金额:$55.51万
-
财政年份:2004
-
负责人:LAURA J ESSERMAN
-
依托单位:
Integrated Biomarkers to Characterize Breast Cancer Risk
-
批准号:6950841
-
项目类别:
-
资助金额:$79.64万
-
财政年份:2004
-
负责人:LAURA J ESSERMAN
-
依托单位:
Integrated Biomarkers to Characterize Breast Cancer Risk
-
批准号:7487841
-
项目类别:
-
资助金额:$75.7万
-
财政年份:2004
-
负责人:LAURA J ESSERMAN
-
依托单位:
Integrated Biomarkers to Characterize Breast Cancer Risk
-
批准号:7282352
-
项目类别:
-
资助金额:$75.37万
-
财政年份:2004
-
负责人:LAURA J ESSERMAN
-
依托单位:
海外基金